Physician profile
Robert E Burton
NPI 1114213253
$3,450.60
in general payments reported to CMS, 2019-2025
33 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $376 · 2021: $113 · 2022: $380 · 2023: $623 · 2024: $652 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.09 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.94 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $466.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $388.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $369.47 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $292.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.07 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.93 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $110.41 | 2022-2025 | |
| Abbott Laboratories | $103.03 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $98.74 | 2020-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $88.24 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $73.58 | 2019-2023 | Camzyos |
| Allergan, INC. | $68.21 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.17 | 2019-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $51.59 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.53 | 2025 | Caplyta |
| Philips North America LLC | $41.77 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Axsome Therapeutics, INC. | $41.76 | 2023-2025 | Sunosi, Auvelity |
| Ibsa Pharma INC. | $35.73 | 2024-2025 | Tirosint, Licart, Flector |
| Sanofi-Aventis U.S. LLC | $32.92 | 2019-2020 | |
| Amarin Pharma, INC. | $32.83 | 2019-2020 | |
| Madrigal Pharmaceuticals | $28.24 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $26.10 | 2023-2024 | |
| Antares Pharma, INC. | $26.00 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Otsuka America Pharmaceutical, INC. | $18.90 | 2024 | Rexulti |
| Ars Pharmaceuticals Operations, INC. | $18.11 | 2025 | Neffy |
| Sanofi Pasteur INC. | $15.19 | 2019 | |
| Exact Sciences Corporation | $14.73 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $14.65 | 2021 | |
| Mylan Specialty L.P. | $14.45 | 2019 | |
| Hikma Pharmaceuticals USA | $14.44 | 2019 | |
| Xeris Pharmaceuticals, INC. | $11.61 | 2021 | |
| Assertio Therapeutics, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.